Our Pipeline

Changing the possible for patients

We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana. We are advancing a number of innovative drug candidates with the goal of disrupting the possible for patients across a diverse set of diseases.

Our Pipeline Header Image

Pipeline

The most advanced programs include an allogeneic CAR T program targeting CD19+ cancers (SC291), an allogeneic CAR T program for autoimmune diseases (SC291), an allogeneic CAR T program targeting CD22+ cancers (SC262), and a stem cell-derived pancreatic islet cell program for persons with type 1 diabetes (SC451). Our expanded access policy for access to our medicines in clinical trials can be found .


Ex Vivo Cell Engineering

Hypoimmune Technology: Donor-derived

Product Candidate Cell Type Potential Indications

SC291 (CD19)

T cells

Oncology



  • Non-Hodgkin lymphoma (NHL)

  • Chronic lymphocytic leukemia (CLL)


Phase 1

ARDENT is a Phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, for relapsed and/or refractory B-cell malignancies.

SC291 (CD19)

T cells

Autoimmune Diseases
  • Lupus nephritis
  • Extrarenal SLE
  • ANCA-associated vasculitis (AAV)
IND cleared

SC262 (CD22)

T cells

Oncology



  • Non-Hodgkin lymphoma (NHL)

  • Acute lymphoblastic leukemia (ALL)

  • Chronic lymphocytic leukemia (CLL)


IND cleared

SC255 (BCMA)

T cells

Oncology

Multiple myeloma


Pre Clinical

Hypoimmune Technology: Stem cell-derived

Product Candidate Cell Type Potential Indications
  • UP421
  • Investigator sponsored trial

Primary islet cells

Diabetes

Type 1 diabetes


CTA authorized

SC451

Islet cells

Diabetes

Type 1 diabetes


Pre Clinical

Stem cell-derived (to migrate to Hypoimmune Technology)

Product Candidate Cell Type Potential Indications

SC379

Glial progenitor cells

Central nervous system (CNS)



  • Huntington’s disease

  • Pelizaeus-Merzbacher disease

  • Secondary progressive multiple sclerosis


Pre Clinical

Expanded Access Policy

Sana is committed to developing safe and effective engineered cells as medicines, which involves evaluation in clinical trials followed by submission of the trial results to regulatory agencies, such as the U.S. Food and Drug Administration (FDA). These investigational therapies have not yet been approved by regulatory authorities. “Expanded access” refers to the use of an unapproved investigational therapy outside of a clinical trial for the potential treatment of a serious or immediately life-threatening condition. We recognize that people living with the diseases we are studying may be interested in accessing our therapies prior to regulatory approval. We want to facilitate a comprehensive understanding of the safety, tolerability, and efficacy of our investigational therapies, which is why monitored participation in clinical trials is the only way to access our investigational therapies. 

If you have additional questions, please speak with your physician. 

Our therapies are investigational and have not been approved by the FDA or any other regulatory agency.